Recursion Pharmaceuticals, Inc.RXRXNASDAQ
Loading
Year-over-year research & development expense growth
Percentile
P4
Near historical low
vs 5Y Ago
-1.2x
Contraction
Streak
3 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | -31.16% |
| Q3 2025 | -5.89% |
| Q2 2025 | -0.77% |
| Q1 2025 | 31.83% |
| Q4 2024 | 31.82% |
| Q3 2024 | 0.91% |
| Q2 2024 | 9.43% |
| Q1 2024 | -2.77% |
| Q4 2023 | -0.75% |
| Q3 2023 | 27.15% |
| Q2 2023 | 17.96% |
| Q1 2023 | 6.13% |
| Q4 2022 | 7.70% |
| Q3 2022 | 6.24% |
| Q2 2022 | 18.49% |
| Q1 2022 | -32.82% |
| Q4 2021 | 45.26% |
| Q3 2021 | 12.23% |
| Q2 2021 | 22.88% |
| Q1 2021 | 16.48% |
| Q4 2020 | 25.18% |
| Q3 2020 | 24.85% |
| Q2 2020 | 3.13% |
| Q1 2020 | 0.00% |